Literature DB >> 24448918

Automated 3D ιnterstitial lung disease εxtent quantification: performance evaluation and correlation to PFTs.

Alexandra Kazantzi1, Lena Costaridou, Spyros Skiadopoulos, Panayiotis Korfiatis, Anna Karahaliou, Dimitris Daoussis, Andreas Andonopoulos, Christina Kalogeropoulou.   

Abstract

In this study, the performance of a recently proposed computer-aided diagnosis (CAD) scheme in detection and 3D quantification of reticular and ground glass pattern extent in chest computed tomography of interstitial lung disease (ILD) patients is evaluated. CAD scheme performance was evaluated on a dataset of 37 volumetric chest scans, considering five representative axial anatomical levels per scan. CAD scheme reliability analysis was performed by estimating agreement (intraclass correlation coefficient, ICC) of automatically derived ILD pattern extent to semi-quantitative disease extent assessment in terms of 29-point rating scale provided by two expert radiologists. Receiver operating characteristic (ROC) analysis was employed to assess CAD scheme accuracy in ILD pattern detection in terms of area under ROC curve (A z ). Correlation of reticular and ground glass volumetric pattern extent to pulmonary function tests (PFTs) was also investigated. CAD scheme reliability was substantial for ILD extent (ICC = 0.809) and distinct reticular pattern extent (0.806) and moderate for distinct ground glass pattern extent (0.543), performing within inter-observer agreement. CAD scheme demonstrated high accuracy in detecting total ILD (A z  = 0.950 ± 0.018), while accuracy in detecting distinct reticular and ground glass patterns was 0.920 ± 0.023 and 0.883 ± 0.024, respectively. Moderate and statistically significant negative correlation was found between reticular volumetric pattern extent and diffusing capacity, forced expiratory volume in 1 s, forced vital capacity, and total lung capacity (R = -0.581, -0.513, -0.494, and -0.446, respectively), similar to correlations found between radiologists' semi-quantitative ratings with PFTs. CAD-based quantification of disease extent is in agreement with radiologists' semi-quantitative assessment and correlates to specific PFTs, suggesting a potential imaging biomarker for ILD staging and management.

Entities:  

Mesh:

Year:  2014        PMID: 24448918      PMCID: PMC4026466          DOI: 10.1007/s10278-013-9670-z

Source DB:  PubMed          Journal:  J Digit Imaging        ISSN: 0897-1889            Impact factor:   4.056


  37 in total

Review 1.  Computer-aided diagnosis and the evaluation of lung disease.

Authors:  Jane P Ko; David P Naidich
Journal:  J Thorac Imaging       Date:  2004-07       Impact factor: 3.000

2.  Lung CT densitometry in systemic sclerosis: correlation with lung function, exercise testing, and quality of life.

Authors:  Gianna Camiciottoli; Ilaria Orlandi; Maurizio Bartolucci; Eleonora Meoni; Francesca Nacci; Stefano Diciotti; Chiara Barcaroli; Maria Letizia Conforti; Massimo Pistolesi; Marco Matucci-Cerinic; Mario Mascalchi
Journal:  Chest       Date:  2007-03       Impact factor: 9.410

3.  Receiver operating characteristic (ROC) analysis: basic principles and applications in radiology.

Authors:  A R van Erkel; P M Pattynama
Journal:  Eur J Radiol       Date:  1998-05       Impact factor: 3.528

4.  Thin-section CT obtained at 10-mm increments versus limited three-level thin-section CT for idiopathic pulmonary fibrosis: correlation with pathologic scoring.

Authors:  E A Kazerooni; F J Martinez; A Flint; D A Jamadar; B H Gross; D L Spizarny; P N Cascade; R I Whyte; J P Lynch; G Toews
Journal:  AJR Am J Roentgenol       Date:  1997-10       Impact factor: 3.959

5.  Observer variation in pattern type and extent of disease in fibrosing alveolitis on thin section computed tomography and chest radiography.

Authors:  C D Collins; A U Wells; D M Hansell; R A Morgan; J E MacSweeney; R M du Bois; M B Rubens
Journal:  Clin Radiol       Date:  1994-04       Impact factor: 2.350

6.  Standardized lung function testing. Official statement of the European Respiratory Society.

Authors: 
Journal:  Eur Respir J Suppl       Date:  1993-03

7.  Computer recognition of regional lung disease patterns.

Authors:  R Uppaluri; E A Hoffman; M Sonka; P G Hartley; G W Hunninghake; G McLennan
Journal:  Am J Respir Crit Care Med       Date:  1999-08       Impact factor: 21.405

8.  HRCT diagnosis of diffuse parenchymal lung disease: inter-observer variation.

Authors:  Z A Aziz; A U Wells; D M Hansell; G A Bain; S J Copley; S R Desai; S M Ellis; F V Gleeson; S Grubnic; A G Nicholson; S P G Padley; K S Pointon; J H Reynolds; R J H Robertson; M B Rubens
Journal:  Thorax       Date:  2004-06       Impact factor: 9.139

9.  CT features of lung disease in patients with systemic sclerosis: comparison with idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia.

Authors:  Sujal R Desai; Srihari Veeraraghavan; David M Hansell; Ageliki Nikolakopolou; Nicole S L Goh; Andrew G Nicholson; Thomas V Colby; Christopher P Denton; Carol M Black; Roland M du Bois; Athol U Wells
Journal:  Radiology       Date:  2004-08       Impact factor: 11.105

10.  Multidetector spiral high-resolution computed tomography of the lungs: distribution of findings on coronal image reconstructions.

Authors:  Takeshi Johkoh; Nestor L Müller; Hironobu Nakamura
Journal:  J Thorac Imaging       Date:  2002-10       Impact factor: 3.000

View more
  2 in total

1.  Outcome Measures for Clinical Trials in Interstitial Lung Diseases.

Authors:  Matthew R Lammi; Robert P Baughman; Surinder S Birring; Anne-Marie Russell; Jay H Ryu; Marybeth Scholand; Oliver Distler; Daphne LeSage; Catherine Sarver; Katerina Antoniou; Kristin B Highland; Otylia Kowal-Bielecka; Joseph A Lasky; Athol U Wells; Lesley Ann Saketkoo
Journal:  Curr Respir Med Rev       Date:  2015

2.  Emphysema progression is visually detectable in low-dose CT in continuous but not in former smokers.

Authors:  Mathilde Marie Winkler Wille; Laura H Thomsen; Asger Dirksen; Jens Petersen; Jesper Holst Pedersen; Saher B Shaker
Journal:  Eur Radiol       Date:  2014-07-20       Impact factor: 5.315

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.